论文部分内容阅读
目的探究生物免疫疗法联合腹腔镜胃癌根治术对患者免疫功能及生活质量的影响。方法 96例胃癌患者,根据术后采取的辅助治疗方式不同分为生物免疫治疗组(54例)和化学治疗组(42例)。两组均行腹腔镜下胃癌根治术,化学治疗组在术后第3周起进行FOLFOX方案,生物免疫治疗组术后给予生物免疫疗法。比较血清中CD3+、CD4+、CD8+淋巴细胞与自然杀伤细胞(NK细胞)的水平变化情况。采用生活质量量表(QOL)评定患者进行手术及辅助治疗后3个月的生活质量。结果 1治疗后,化学治疗组血清CD3+、CD4+、CD4+/CD8+与NK细胞水平明显下降,差异具有统计学意义(P<0.05);生物免疫治疗组血清CD3+、CD4+、CD4+/CD8+与NK细胞水平明显上升,差异具有统计学意义(P<0.05);治疗后生物免疫治疗组血清CD3+、CD4+、CD4+/CD8+与NK细胞水平高于化学治疗组,差异具有统计学意义(P<0.05)。2治疗后,化学治疗组QOL评分为(5.74±1.03)分,生物免疫治疗组为(7.43±1.31)分,比较差异有统计学意义(P<0.05)。3治疗后,生物免疫治疗组完全缓解14例(25.9%)、部分缓解33例(61.1%)、稳定4例(7.4%)、进展3例(5.6%),总有效率为87.0%;化学治疗组完全缓解8例(19.0%)、部分缓解21例(50.0%)、稳定9例(21.4%)、进展4例(9.5%),总有效率为69.0%;两组总有效率比较,差异具有统计学意义(P<0.05)。结论生物免疫疗法联合腹腔镜胃癌根治术创伤小、恢复快,能促进术后免疫损伤的恢复,防止肿瘤复发与转移,降低术后复发率,提高患者生活质量,值得临床推广。
Objective To investigate the effects of bio-immunotherapy combined with laparoscopic radical gastrectomy on immune function and quality of life in patients. Methods Ninety-six patients with gastric cancer were divided into two groups: immunotherapy group (n = 54) and chemotherapy group (n = 42) according to the mode of postoperative adjuvant therapy. Both groups underwent laparoscopic radical gastrectomy. The chemotherapy group received FOLFOX regimen at the third week after the operation, and the bio-immunotherapy group received bio-immunotherapy after the operation. Serum CD3 +, CD4 +, CD8 + lymphocytes and natural killer cells (NK cells) level changes. Quality of Life Scale (QOL) was used to assess the quality of life of patients 3 months after surgery and adjuvant therapy. Results After treatment, the serum levels of CD3 +, CD4 +, CD4 + / CD8 + and NK cells in the chemotherapy group decreased significantly (P <0.05). The levels of CD3 +, CD4 +, CD4 + / CD8 + (P <0.05). After treatment, the level of serum CD3 +, CD4 +, CD4 + / CD8 + and NK cells in the group of immunotherapy were significantly higher than that in the chemotherapy group (P <0.05). 2 after treatment, the QOL score of the chemotherapy group was (5.74 ± 1.03) points, and the group of immunotherapy was (7.43 ± 1.31) points, the difference was statistically significant (P <0.05). After treatment, 14 patients (25.9%) were relieved completely, 33 patients (61.1%) partially relieved, 4 patients (7.4%) were stabilized, 3 patients (5.6%) progressed, and the total effective rate was 87.0% In the treatment group, complete remission was achieved in 8 cases (19.0%), partial remission in 21 cases (50.0%), stabilization in 9 cases (21.4%), progression in 4 cases (9.5%), and total effective rate was 69.0% The difference was statistically significant (P <0.05). Conclusions Bioimmunotherapy combined with laparoscopic radical gastrectomy has the advantage of less trauma and faster recovery, which can promote the recovery of postoperative immune injury, prevent the recurrence and metastasis of tumor, reduce the recurrence rate and improve the quality of life of patients, which deserves clinical promotion.